Skip to content
A New Therapy Offers A Different Approach to Inhibiting the Complement System episode artwork

May 28, 2021 21 min

A New Therapy Offers A Different Approach to Inhibiting the Complement System

from RARECast

Earlier the month the U.S. Food and Drug Administration approved Apellis Pharmaceuticals Empaveli to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening condition in which the body’s immune system destroys the oxygen carrying red blood cells. Like existing treatments Soliris and Ultomiris, Empaveli works to inhibit the complement system, but it is the first therapy to target the portion of this immune cascade known as C3. We spoke to Cedric Francois, co-founder and CEO of Apellis, about Empaveli, what advantages it may provide over existing therapies for PNH, and other indications the company will pursue for this medicine.

Episode details come from the podcast's RSS feed.

Embed this episode

Cedric Francois, co-founder and CEO of Apellis, discusses the recent FDA approval of the PNH therapy Empaveli, what advantages it may provide over existing therapies, and other indications the company will pursue for this medicine.

Ready to play

A New Therapy Offers A Different Approach to Inhibiting the Complement System

0:00 21:15

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 21 minutes long.

When was this RARECast episode published?

This episode was published on May 28, 2021.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.